ArticleBMC immunology2026
Predictive value of miR-151a-3p for the onset of sepsis-induced acute kidney injury and its functional role during disease development.
Article in BMC immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSepsis-associated acute kidney injury (SA-AKI) is a significant clinical challenge due to its prevalence in intensive care units. This study evaluated the diagnostic utility of serum miR-151a-3p for SA-AKI, aiming to provide new insights into early diagnosis and mechanistic research.
methodsSerum miR-151a-3p levels were determined via qRT-PCR and assessed for clinical correlations (Pearson correlation), risk association with SA-AKI (logistic regression), and diagnostic efficacy (ROC curve analysis). In vitro, the injury model was constructed by inducing TCMK-1 cells with LPS, and the miR-151a-3p mimic was transfected to observe its effects on inflammatory and oxidative stress. Finally, a binding relationship between miR-151a-3p and AKT3 was validated by employing both bioinformatics and dual-luciferase assay.
resultsIn SA-AKI patients, miR-151a-3p was significantly decreased, and its expression level showed a significant negative correlation with disease severity and representative indicators of renal function. MiR-151a-3p is an independent protective factor for SA-AKI, with an AUC of 0.883 for predicting SA-AKI. In vitro experiments confirmed that overexpression of miR-151a-3p significantly alleviated LPS-induced inflammatory responses and oxidative stress damage. The dual-luciferase assay confirmed the binding relationship between AKT3 and miR-151a-3p.
conclusionsMiR-151a-3p is closely related to the severity of SA-AKI. It can be used as a potential biomarker for the early prediction of the occurrence of SA-AKI. Overexpression of miR-151a-3p alleviates LPS-induced renal tubular epithelial cell injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.